Panagiotou Grigorios, Babazadeh Demsina, Mazza Dario F, Azghadi Soheila, Cawood Joseph M, Rosenberg Aaron S, Imamura Fumiaki, Forouhi Nita G, Chaudhari Abhijit J, Abdelhafez Yasser G, Badawi Ramsey D, Chondronikola Maria
MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Department of Nutrition, University of California Davis, Davis, CA, USA.
Clin Nutr. 2025 Feb;45:262-269. doi: 10.1016/j.clnu.2024.12.028. Epub 2024 Dec 30.
BACKGROUND & AIMS: Brown adipose tissue (BAT) has been mainly investigated as a potential target against cardiometabolic disease, but it has also been linked to cancer-related outcomes. Although preclinical data support that BAT and the thermogenic adipocytes in white adipose tissue may play an adverse role in the pathogenesis of cancer cachexia, results from studies in patients have reported inconsistent results. The purpose of this study was to examine the interrelationship between presence of detectable BAT, changes in body weight, and cachexia in patients with cancer. We hypothesized that evidence of BAT at cancer diagnosis would be associated with greater weight loss and risk of cancer cachexia up to a year after cancer diagnosis.
We conducted a retrospective cohort study in treatment-naïve patients with detectable BAT (BAT+, n = 57) and without evidence of BAT (BAT-, n = 73) on 2-deoxy-2-[F]fluoro-d-glucose positron emission tomography-computed tomography (F-FDG-PET-CT) imaging performed for cancer staging (2004-2020). Patients' clinical, demographic, and anthropometric characteristics were extracted from their electronic medical record for up to a year after diagnosis. The two groups were a priori matched for demographic, anthropometric, and disease-related characteristics at diagnosis, as well as for season and outdoor temperature on the day of the PET-CT scan. Cancer cachexia was defined as weight loss greater than 5 % or 2 % if body mass index was lower than 20 kg/m. Poisson regression models were fitted to estimate the relative risk (RR) for developing cancer cachexia over the 1-year follow-up among BAT+ compared to BAT- patients.
The BAT+ group experienced a lower magnitude of weight loss compared with the BAT- group during the 1-year follow-up (p = 0.014 for interaction between BAT status and time). The risk for cancer cachexia was 44 % lower in the BAT+ than the BAT- group, adjusted for age, sex, outdoor temperature on the day of the F-FDG-PET-CT imaging, cancer site and stage (RR: 0.56, 95 % CI: 0.32 to 0.97).
Contrary to our original hypothesis, evidence of BAT assessed by F-FDG-PET-CT imaging at cancer diagnosis was associated with greater body weight maintenance and lower risk for developing cancer cachexia up to one year after diagnosis. Larger, prospective studies and mechanistic experiments are needed to expand and identify the causal factors of our observations.
棕色脂肪组织(BAT)主要被作为对抗心脏代谢疾病的潜在靶点进行研究,但它也与癌症相关结局有关。尽管临床前数据支持BAT和白色脂肪组织中的产热脂肪细胞可能在癌症恶病质的发病机制中起不良作用,但患者研究的结果却报告了不一致的结果。本研究的目的是探讨癌症患者中可检测到的BAT的存在、体重变化和恶病质之间的相互关系。我们假设癌症诊断时BAT的证据与癌症诊断后长达一年的更大体重减轻和癌症恶病质风险相关。
我们对2004年至2020年期间在接受癌症分期的2-脱氧-2-[F]氟-D-葡萄糖正电子发射断层扫描-计算机断层扫描(F-FDG-PET-CT)成像中可检测到BAT(BAT+,n = 57)且无BAT证据(BAT-,n = 73)的初治患者进行了一项回顾性队列研究。从患者的电子病历中提取诊断后长达一年的临床、人口统计学和人体测量学特征。两组在诊断时的人口统计学、人体测量学和疾病相关特征以及PET-CT扫描当天的季节和室外温度方面进行了先验匹配。癌症恶病质定义为体重减轻超过5%,如果体重指数低于20kg/m²则为超过2%。采用泊松回归模型来估计BAT+组与BAT-组在1年随访期间发生癌症恶病质的相对风险(RR)。
在1年随访期间,BAT+组的体重减轻幅度低于BAT-组(BAT状态与时间之间的交互作用p = 0.014)。在调整了年龄、性别、F-FDG-PET-CT成像当天的室外温度、癌症部位和分期后,BAT+组发生癌症恶病质的风险比BAT-组低44%(RR:0.56,95%CI:0.32至0.97)。
与我们最初的假设相反,癌症诊断时通过F-FDG-PET-CT成像评估的BAT证据与诊断后长达一年的更大体重维持和更低的癌症恶病质发生风险相关。需要更大规模的前瞻性研究和机制实验来扩展和确定我们观察结果的因果因素。